These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Management of "refractory" skin disease in patients with lupus erythematosus. Callen JP Best Pract Res Clin Rheumatol; 2005 Oct; 19(5):767-84. PubMed ID: 16150402 [TBL] [Abstract][Full Text] [Related]
43. The incidence of herpes zoster in cutaneous lupus erythematosus (CLE), dermatomyositis (DM), pemphigus vulgaris (PV), and bullous pemphigoid (BP). Robinson ES; Payne AS; Pappas-Taffer L; Feng R; Werth VP J Am Acad Dermatol; 2016 Jul; 75(1):42-8. PubMed ID: 27317514 [TBL] [Abstract][Full Text] [Related]
44. Where Should We Position Antimalarial Drug Combinations in the Management of Refractory Cutaneous Lupus Erythematosus? Pérez-López I; Martínez-López A; Tercedor-Sánchez J; Ruiz-Villaverde R Actas Dermosifiliogr; 2016; 107(6):521-2. PubMed ID: 26762693 [No Abstract] [Full Text] [Related]
48. Systemic Treatment for Clinically Amyopathic Dermatomyositis at 4 Tertiary Care Centers. Pinard J; Femia AN; Roman M; Alsarheed A; Joyce C; Lin J; Vleugels RA JAMA Dermatol; 2019 Apr; 155(4):494-496. PubMed ID: 30673076 [TBL] [Abstract][Full Text] [Related]
49. Quinacrine Suppresses Tumor Necrosis Factor-α and IFN-α in Dermatomyositis and Cutaneous Lupus Erythematosus. Alves P; Bashir MM; Wysocka M; Zeidi M; Feng R; Werth VP J Investig Dermatol Symp Proc; 2017 Oct; 18(2):S57-S63. PubMed ID: 28941496 [TBL] [Abstract][Full Text] [Related]
50. [Synthetic antimalarials and skin]. Ribrioux A Ann Dermatol Venereol; 1990; 117(12):975-90. PubMed ID: 2150584 [No Abstract] [Full Text] [Related]
51. The Cutaneous Lupus Erythematosus Disease Activity and Severity Index: expansion for rheumatology and dermatology. Krathen MS; Dunham J; Gaines E; Junkins-Hopkins J; Kim E; Kolasinski SL; Kovarik C; Kwan-Morley J; Okawa J; Propert K; Rogers N; Rose M; Thomas P; Troxel AB; Van Voorhees A; Feldt JV; Weber AL; Werth VP Arthritis Rheum; 2008 Mar; 59(3):338-44. PubMed ID: 18311759 [TBL] [Abstract][Full Text] [Related]
52. Beneath the surface: derm clues to underlying disorders. Halvorson CR; Colgan R J Fam Pract; 2010 Oct; 59(10):562-72. PubMed ID: 20922176 [TBL] [Abstract][Full Text] [Related]
53. Dapsone as Second-Line Treatment for Cutaneous Lupus Erythematosus? A Retrospective Analysis of 34 Patients and a Review of the Literature. Klebes M; Wutte N; Aberer E Dermatology; 2016; 232(1):91-6. PubMed ID: 26606129 [TBL] [Abstract][Full Text] [Related]
54. Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial. Okon L; Rosenbach M; Krathen M; Rose M; Propert K; Okawa J; Werth V J Am Acad Dermatol; 2014 Mar; 70(3):583-4. PubMed ID: 24528907 [No Abstract] [Full Text] [Related]
55. Characteristics and Alternative Treatment Outcomes of Antimalarial-Refractory Cutaneous Lupus Erythematosus. Fruchter R; Kurtzman DJB; Patel M; Merola J; Franks AG; Vleugels RA; Femia AN JAMA Dermatol; 2017 Sep; 153(9):937-939. PubMed ID: 28636714 [TBL] [Abstract][Full Text] [Related]
56. Current treatment of cutaneous lupus erythematosus. Werth V Dermatol Online J; 2001 Feb; 7(1):2. PubMed ID: 11328623 [TBL] [Abstract][Full Text] [Related]
57. Efficacy of topical tacrolimus in the treatment of various cutaneous manifestations of lupus erythematosus. von Pelchrzim R; Schmook T; Friedrich M; Worm M Int J Dermatol; 2006 Jan; 45(1):84-5. PubMed ID: 16426386 [No Abstract] [Full Text] [Related]